NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia.

Autor: Shang CY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Bei LY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Wu JZ; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Sheng HR; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Yin H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Liang JH; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Wang L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Li JY; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China., Li Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. cph7707@126.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. cph7707@126.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. cph7707@126.com., Xu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. xuwei10000@hotmail.com.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. xuwei10000@hotmail.com.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. xuwei10000@hotmail.com.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2024 Mar; Vol. 103 (3), pp. 833-841. Date of Electronic Publication: 2023 Nov 23.
DOI: 10.1007/s00277-023-05554-2
Abstrakt: Chronic lymphocytic leukemia (CLL) patients with hepatitis B virus (HBV) infection have a poor prognosis, underlying mechanism remains unclear. NOTCH mutations are frequent in CLL and associated with disease progression and drug resistance. It is also reported to be associated with hepatitis infection in lymphoid malignancies. In order to investigate the relation between the NOTCH pathway and HBV-associated CLL, we studied 98 previously untreated HBV-positive CLL patients and 244 HBV-negative CLL. NOTCH mutations were more frequent in HBV-positive CLL subgroup (p = 0.033). By survival analysis, HBV infection was associated with disease progression and poor survival (p = 0.0099 for overall survival (OS) and p = 0.0446 for time-to-treatment (TTT)). Any lesions of the NOTCH pathway (NOTCH1, NOTCH2, and SPEN) aggravated prognosis. In multivariate analysis, NOTCH mutation retained an independent significance for HBV-infected patients (p = 0.016 for OS and p = 0.023 for TTT). However, HBV positive with NOTCH unmutated had no statistical difference in prognosis compared with HBV-negative patients (p = 0.1706 for OS and p = 0.2387 for TTT), which indicated that NOTCH pathway mutation contributed to inferior prognosis in HBV-infected CLL. In conclusion, a cohort of CLL patients with HBV positive displayed a worse clinical outcome and the status of the NOTCH signaling pathway might play a crucial role.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: